Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | TKT | P29401 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30391719 | 1.00 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL20099915 | 0.86 | CXCR4 (0.44) | ALDH1A1L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL243610 | 0.83 | — | — | |
| SCHEMBL10245894 | 0.81 | NOS2 (0.45) | ALDH1A1L3MBTL1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL11418372 | 0.81 | NOS3 (0.45) | ALDH1A1L3MBTL1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL10765635 | 0.81 | L3MBTL1 (0.57) | ALDH1A1L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL14367869 | 0.80 | PKM (0.48) | ALDH1A1L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL27420489 | 0.79 | CXCR4 (0.37) | ALDH1A1L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL701433 | 0.79 | NOS3 (0.48) | ALDH1A1L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL30839509 | 0.79 | NOS3 (0.48) | ALDH1A1L3MBTL1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| WO-2022210479-A1 | USE OF AZEPANE DERIVATIVE FOR TREATMENT, AMELIORATION OR PREVENTION OF κ-OPIOID RECEPTOR-RELATED DISEASES | 日本ケミファ株式会社 | 2022-10-06 | — | — | WO | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| EP-1507511-A1 | PERSONAL CARE COMPOSITIONS WITH HYDROXY AMINE NEUTRALIZED POLYMERS | UNILEVER PLC (GB) | 2005-02-23 | — | — | EP | disclosed |
| EP-1507512-A1 | COSMETIC COMPOSITIONS WITH HYDROXY AMINE SALTS OF MALONIC ACID | UNILEVER PLC (GB) | 2005-02-23 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20030228337-A1 | Personal care compositions with hydroxy amine neutralized polymers | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003099253-A1 | PERSONAL CARE COMPOSITIONS WITH HYDROXY AMINE NEUTRALIZED POLYMERS | UNILEVER PLC (GB) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099252-A1 | COSMETIC COMPOSITIONS WITH HYDROXY AMINE SALTS OF MALONIC ACID | UNILEVER PLC (GB) | 2003-12-04 | — | — | WO | disclosed |
| US-20030224023-A1 | Cosmetic compositions with hydroxy amine salts of malonic acid | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6291596-B1 | CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT | JSR CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0974602-A1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030224023-A1 | Cosmetic compositions with hydroxy amine salts of malonic acid | CUTA, TYR, DDC | ALDH1A1 281/4885L3MBTL1 3352/4885NOS3 2350/4885 |
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2943/4885L3MBTL1 2715/4885NOS3 4813/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2681/4885L3MBTL1 2705/4885NOS3 4805/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | ALDH1A1 1816/4885L3MBTL1 3074/4885NOS3 4323/4885 |
| US-20030228337-A1 | Personal care compositions with hydroxy amine neutralized polymers | CUTA, PARN, POLH | ALDH1A1 1635/4885L3MBTL1 3879/4885NOS3 2065/4885 |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ALDH1A1 3316/4885L3MBTL1 1519/4885NOS3 3903/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ALDH1A1 3316/4885L3MBTL1 1519/4885NOS3 3903/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | ALDH1A1 1957/4885L3MBTL1 3390/4885NOS3 4805/4885 |
| US-11453683-B1 | KRas G12D inhibitors | KRAS, NRAS, HRAS | ALDH1A1 2055/4885L3MBTL1 3454/4885NOS3 4801/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2681/4885L3MBTL1 2705/4885NOS3 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.